Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis.

IF 2.7 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-08-19 DOI:10.1080/1750743X.2024.2379230

Alexander B Karol, Yu Fujiwara, Tyler D'Ovidio, Elena Baldwin, Himanshu Joshi, Deborah B Doroshow, Matthew D Galsky

{"title":"Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis.","authors":"Alexander B Karol, Yu Fujiwara, Tyler D'Ovidio, Elena Baldwin, Himanshu Joshi, Deborah B Doroshow, Matthew D Galsky","doi":"10.1080/1750743X.2024.2379230","DOIUrl":null,"url":null,"abstract":"Background: Tumor-promoting inflammation and inflammatory cytokines are linked to immune checkpoint blockade (ICB) resistance.Methods: We assessed the associations between pre-treatment Interleukin-6 (IL-6), Interleukin-8 (IL-8) levels and on-treatment changes in IL-6, IL-8 and C-reactive protein (CRP) with ICB trial end points.Results: 27 studies representing 6,719 patients were included. Low pre-treatment IL-6 levels were associated with improved objective response rate (ORR) (odds ratio (OR) = 0.31 [0.18-0.55]) and better progression-free survival (PFS) (hazard ratio (HR) = 0.59 [0.48-0.72]) and overall survival (OS) [95% confidence interval (CI)] (HR = 0.42 [0.35-0.50]). Low pre-treatment IL-8 levels were associated with improved ORR (OR = 0.47 [0.36-0.61]) and better PFS (HR = 0.65 [0.58-0.74]) and OS (HR = 0.44 [0.39-0.51]). On-treatment decline in CRP was associated with improved ORR (OR = 0.18 [0.11-0.20]), PFS (HR = 0.40 [0.31-0.91]) and OS (HR = 0.48 [0.40-0.58]).Conclusion: Peripheral blood cytokines warrant further evaluation as enrichment and pharmacodynamic biomarkers for strategies targeting tumor-promoting inflammation.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"829-840"},"PeriodicalIF":2.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11457654/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1750743X.2024.2379230","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/19 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Tumor-promoting inflammation and inflammatory cytokines are linked to immune checkpoint blockade (ICB) resistance.Methods: We assessed the associations between pre-treatment Interleukin-6 (IL-6), Interleukin-8 (IL-8) levels and on-treatment changes in IL-6, IL-8 and C-reactive protein (CRP) with ICB trial end points.Results: 27 studies representing 6,719 patients were included. Low pre-treatment IL-6 levels were associated with improved objective response rate (ORR) (odds ratio (OR) = 0.31 [0.18-0.55]) and better progression-free survival (PFS) (hazard ratio (HR) = 0.59 [0.48-0.72]) and overall survival (OS) [95% confidence interval (CI)] (HR = 0.42 [0.35-0.50]). Low pre-treatment IL-8 levels were associated with improved ORR (OR = 0.47 [0.36-0.61]) and better PFS (HR = 0.65 [0.58-0.74]) and OS (HR = 0.44 [0.39-0.51]). On-treatment decline in CRP was associated with improved ORR (OR = 0.18 [0.11-0.20]), PFS (HR = 0.40 [0.31-0.91]) and OS (HR = 0.48 [0.40-0.58]).Conclusion: Peripheral blood cytokines warrant further evaluation as enrichment and pharmacodynamic biomarkers for strategies targeting tumor-promoting inflammation.

查看原文本刊更多论文

外周血细胞因子与免疫检查点阻断疗法的疗效：系统综述与荟萃分析。

背景：促进肿瘤生长的炎症和炎性细胞因子与免疫检查点阻断剂（ICB）的耐药性有关。研究方法我们评估了治疗前白细胞介素-6 (IL-6)、白细胞介素-8 (IL-8)水平以及治疗中IL-6、IL-8和C反应蛋白(CRP)的变化与ICB试验终点之间的关联。结果：共纳入了代表 6719 名患者的 27 项研究。治疗前低IL-6水平与客观反应率（ORR）改善（几率比（OR）= 0.31 [0.18-0.55]）、无进展生存期（PFS）改善（危险比（HR）= 0.59 [0.48-0.72]）和总生存期（OS）改善[95%置信区间（CI）]（HR = 0.42 [0.35-0.50]）相关。治疗前 IL-8 水平较低与 ORR（OR = 0.47 [0.36-0.61]）、PFS（HR = 0.65 [0.58-0.74]）和 OS（HR = 0.44 [0.39-0.51]）的改善相关。治疗中 CRP 的下降与 ORR（OR = 0.18 [0.11-0.20]）、PFS（HR = 0.40 [0.31-0.91]）和 OS（HR = 0.48 [0.40-0.58]）的改善相关。结论外周血细胞因子作为针对肿瘤促进炎症策略的富集和药效生物标记物，值得进一步评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.